A Phase 1b trial of EB8018 in patients with Crohn's disease who have active inflammation of the gut
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2018
At a glance
- Drugs EB 8018 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Sponsors Enterome
- 01 Jun 2018 According to an Enterome media release, first patient is expected to be enrolled and dosed in the coming weeks.
- 01 Jun 2018 Status changed from planning to recruiting, according to an Enterome media release.
- 30 Oct 2017 New trial record